Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih‐Hsin Yang, Yi-Long Lung Cancer Wu, Martin Schüler et al. · The Lancet Oncology · 2015
Cited by 1,571 works. doi:10.1016/s1470-2045(14)71173-8 Open-access PDF
Authors
- James Chih‐Hsin Yang
- Yi-Long Lung Cancer Wu
- Martin Schüler
- Martin Sebastian
- Sanjay Popat
- Nobuyuki Yamamoto
- Caicun Zhou
- Cheng-Ping Hu
- Kenneth John O'Byrne
- Jifeng Feng
- Shun Lü
- Yunchao Huang
- Sarayut Lucien Geater
- Kye Young Lee
- Chun‐Ming Tsai
- В. А. Горбунова
- Vera Hirsh
- Jaafar Bennouna
- С. В. Орлов
- Tony S.K. Mok
References
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Modelling for Survival Data in Medical Research
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
- Epidermal growth factor receptor mutations in lung cancer
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)